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Atrialn&iureticpeptideisapeptidebonuoneefawiiacorlgin, 
wbkbbrekamdiarespeasetoatrialdiillsiellaadservesto 
mabWinsodium~ and hlbibit activation dtbe lwldn- 
a@oten&=aldestemue sy6tem. Congestive b art fLaibwe is a 
dhdcalsyudmmedruwterlzedbyiucrewdcardiacvobunepnd 
premureoverleadwitbmiaabiitoexcreteasodiumload, 
wbkbisassedatedwitblacreasedactivItyof~ma~u= 
moralandlocalaute&neandpuarrineme&anis~Ciilati~ 
atrialaahWetkpeptideisgreaUyincrewliaamgestivehcert 
Mlureasaresaltofbweasedsyntbesisaadreleaseoftbis 
hormone.Atridnatriureticpeptidebasemergedasm~t 
d@mticadpmgmodcserummarkerhco~eheart 
It is oow well established that he heart is an endocrine gland 
that synthesizes and releases the peptide hormone atrial 
natriuretic peptide. The worlc of Kisch (11 first suggested 
such a role for the heart with e observation f membrane 
bound storage granules, referred to as specific granules in 
atrial cardiocytes. The density of these granules was re- 
ported to be affected by various experimental procedures, 
such as changes in fluid and electrolyte balance (2). The 
physiologic significance of these atrial granules was estab- 
lished when de Bold et al. (3) observed intheir seminal study 
a natrhuetic and hypotensive effect in response to intrave- 
nous injection of atrial extracts into rats. These hallmark 
investigations led to the characterization of atrial natrhuetic 
peptide as a 28-residue C-terminal peptide derived from a 
126-amine acid precursor pro-atrial natriuretic peptide that 
is the principal storage form (4). Repeated studies (S-7) have 
demonstrated hat atrial natriuretic peptide possesses unique 
biologic actions that include natriuretic, vasodilator, renin- 
and aldosterone-inhibiting and antimitogenic actions. 
Although the cellular mechanism for atrial natriuretic 
peptide synthesis and processing continues to emerge, Ed- 
wards et al. (8) have shown, in an elegant study creating 
cardiac tamponade in animals, that atrial stretch is the 
principal stimulus for atrial natriuretic peptide secretion, 
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bibwe. In eariy bet134 ibiiure, it may piay a key role in presetig 
the compeasated state of asymptomatic left ventricular dysfimc- 
Uon. Despite inawsed dradatig atrial natriuretic peptide io
beart failure, tbe kidaey retab~ sodium and is byperespousive to 
exogemm and endogen~ atrial natrhetic peptide. The me&- 
aaism Tar the attenuated renal response is multktodal and 
Indudes renal hypeperkdon, activation f the renin4ngiotensin- 
aldosterone a d sympathetic nervous systems. Thwapeutle strat- 
egies to ~ntiate tbe bielogic a tk ofatrial natriuretic peptide 
may prolong the asymptomatic phase aud delay progressIon t  
overt wngestive h art f&ilure. 
(3 Am Coil Cardid 1993;22[Supplement A].%&92A) 
Cardiac tamponade produced a balanced increase in intra- 
atrial and pericardii pressures with no change in atrial 
transmural pressure or atrial stretch. No change incirculat- 
ing atrial natriuretic peptide was observed. In contrast, great 
artery constriction resulted in increased transmural pressure 
and atrial stretch in association with elevated plasma trial 
natriuretic peptide concentrations. This mechanism explains 
release of this hormone voked by a variety of maneuvers 
and conditions associated with central volume overload 
(9-l 1). The cellular mechanism underlying stretch-mediated 
atrial natriuretic peptide release isdependent on an increase 
in cytosolic alcium with activation of the phosphoinositide 
pathway (12). 
Two receptors that interact with atrial natriuretic peptide 
have been identified (13). A biologically active receptor 
termed the ANPR-A receptor is linked to the activation of 
particulate guanylate cyclase. Binding of atrial natriuretic 
peptide to this receptor results in an increase in guanosine 
3’,5’-cyclic monophosphate (cyclic GMP), which leads to 
the biologic actions of atrial natriuretic peptide in many 
tissues. The most abundant receptor for atrial natrituetic 
peptide, however, is a biologically silent clearance receptor 
termed the ANPR-C receptor, which functions to bind and 
clear atrial natriuretic peptide from the circulation (14). After 
binding, receptor-mediated en ocytosis occurs with intracel- 
lular degradation. 
Congestive heart failure represents a state in which 
cardiac synthesis and release of atrial natriuretic peptide 
exceed those of all other states (Pi. 1). In this brH review, 
we will attempt to provide an update on important issues 
regarding atrial natriuretic peptide in congestive heart fail- 
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Figure 1. Plasma concentrations of atrial natriuretic peptide (ANF) 
in normal humans and three groups of patients (pt.) with cardiovas- 
cular disease. Normal (Nl) atria1 pressure, and increased atria1 
pressure without or with congestive h art failure (CHF) are shown. 
Reprinted, with permission, from Burnett et al. (24). 
ure, with a focus on its biologic ro!e inasymptomatic left 
ventricular dysfunction, mechanisms of atrial natriuretic 
peptide hyporesponsiveness in severe heart failure, cardiac 
synthesis in heart failure, diagnostic and prognostic signill- 
cance of natriuretic peptide in heart failure and a novel 
therapeutic strategy of employing endogenous atrial natri- 
uretic peptide in the treatment ofheart failure by inhibiting 
its enzymatic degradation. 
dysfunction to preserve cardiorenal homeostasis, contribute 
timics the humoral profile of patients with asymptomatic 
to the maintenance of sodium bdance and inhibit activation 
of the renin-angiotensin-aldosterone system despite ventric- 
left ventricular dysfunction reported in SOLVD and was 
ular dysfunction. Such a conclusion is supported by a 
number of key observations. In a low attial natriuretic 
characterized by significant ventricular dysfunction without 
peptide model of acute congestive heart failure produced by 
thoracic inferior vena cava constriction that is characterized 
sodium retention in association with elevated atrial natri- 
by decreased cardiac output without increases in atrial 
pressures or atrial natriuretic peptide, marked sodium 
retention, vasoconstriction a d activation of the renin- 
angiotensin-aldosterone system resulted. These findings 
were not observed ina high atria1 natriuretic peptide model 
produced by rapid ventricular p cing despite similar educ- 
tions in cardiac output and mean arterial pressure (20). 
Exogenous administration of atrial natriuretic peptide in 
dogs with caval constriction tomimic circulating concentra- 
tions encountered in a high atrial natriuretic peptide model of 
heart failure prevented sodium retention, vasoconstriction 
and activation of the renin-angiotensin-aldosterone system 
(Fig. 2). Margulies et al. (21) observed significant atriuresis 
and renal cyclic GMP generation with elevation of plasma 
atrial natriuretic peptide after the onset of ventricular dys- 
function. Awazu et al. (22) tested the effect of anti-atrial 
natriuretic peptide antibodies in amodel of chronic onges- 
tive heart failure in rats. Bolus injection of atrial natriuretic 
peptids-neutralizing a tibodies resulted in fwther sodium 
retention without aifecting systemic blood pressure or glo- 
men&u filtration rate. More recently, Redlield et al. (23) 
reported on cardiorenal fimction in a conscious canine model 
of asymptomatic left ventricular dysfunction. This model 
Functional Role of Atrial Natriuretic Peptide 
Several welI designed therapeutic trials (15-18) have 
demonstrated drug efficacy in improving functional capacity 
and survival. The fact that patients classified in New York 
in Early Heart Failure and Mechanisms of
Heart Association functional cl ss I or II experienced sig- 
n&ant benefit and that drug intervention was not com- 
Hyporesponsiveness in Severe Heart Failure 
pletely effective in halting the progressive worsening process 
leadii to death (16) has shifted an interest to patients in 
early stages of heart failure. The National Institutes of 
Health-sponsored Studies of Left Ventricular Dysfunction 
(SOLVD) (19) in patients with chronic left ventricular dys- 
function but without signs of overt heart failure (that is, 
asymptomatic left ventricular dysfunction,) demonstrated 
humtial activation that is characterized byan increase in 
circulating atrial natriuretic peptide without activation of the 
circulating renin-angiotensin-aldosterone system in the ab- 
sence of diuretic treatment. The known biology of the atrial 
natriuretic peptide system suggests his cardiac peptide may 
play a key role in preserving this compensated sta’*e of 
asymptomatic lefi ventricular dysfunction. 
uretic peptide and no activation of the renin-a@otensin- 
aldosterone system. In response to acute intravascular vol- 
ume expansion, ormal release of atrial natriuretic peptide 
and an intact renal natriuretic response were observed. 
These investigator8 concluded that increased atrial natri- 
uretic peptide is a marker for cardiac volume overload in 
early congestive h art failure and contributes tothe mainte- 
nance of sodium balance and inhibition of the rmin- 
angiotensin-aldosterone syst m in asymptomatic left ven- 
tricular dysfunction. They speculated that therapeutic 
strategies that potentiate he biologic actions of atrial natri- 
uretic peptide may prolong the asymptomatic phase of 
ventricular dysfunction and delay progression toovert con- 
gestive heart failure. 
RenaI hyporesponsivenes8 to atrial natrIuretIe peptide in 
overt congestive heart failure. Severe congestive heart fail- 
ure is a syndrome characterized bysodium retention and 
activation of the renin-angiotensin-aldosterone system with 
elevation of circulating atrial natriuretic peptide (2425). 
Humans and animal models of chronic congestive heart 
failure are characterized by an attenuated natriuretic re- 
sponse to endogenous aud exogenous atrial natriuretic pep- 
Atrial natrhm& peptide and asymptomatIc Ieft vent&u- 
lar dysbnction. Evidence supports an important role for 
atrial natriuretic peptide in asymptomatic left ventricular 
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figure 2. Effect of rapid right ventricular pacing-induced ongestive 
heart Like (CID, .noracic vena cad constriction and thoracic 
vena cavai constriction (TIVC) plus exogenous atrial natriuretic 
peptide (TIVC + ANFj on mean arterial pressure (MAP), plasma 
atrial naniuretic peptide, urinary sodium excretion (&,V, plasma 
renin activity (PRA) and plasma ldosterone (Aldo). *p < 0.05 
experiment or recovw -vs. controk tp < 0.01 experiment or
recovery vs. control. AtI data are expressed asmean value +. SEM. 
Reproduced, with peenission, from Lee et al. (20). 
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tide (21,26-29). It has been suggested that the diminished 
renal response to he hormone plays an important role in the 
pathophysiology of sodium retention and systemic and renal 
vasoconstriction bserved in overt heart failure. The mech- 
anisms responsible for the renal hyporesponsiveness to atrial 
natriuretic peptide in congestive heart ftihue are most likely 
muhifactorkd and include a decrease in renal perfusion 
pressure (29), increased activity of functional antagonists to 
atrial natriuretic peptide such as the renin-angiotensin- 
aldosterone system (30), renal sympathetic nerve activity 
(31) and circulating noradrenaiine (32), atrial natriuretic 
peptide receptor downregulation (33) and possibly enhanced 
enzymatic degradation f atrial natriuretic peptide (34). 
Increased activity of the renin-angiotensin-aldosterone 
system plays a key role in mediating the blunted renal 
response to atria1 natriuretic peptide in overt congestive 
heart failure. The natriuretic response to exogenous atrial 
natriuretic peptide in salt-retaining rats with chronic arterio- 
venous fistula could be restored with long-term treatment 
with the angiotensin-converting enzyme inhibitor enalapril 
(35). This response occurred espite a decrease in mean 
arterial blood pressure and was unrelated to changes in 
endogenous levels of atrial natriuretic peptide. The mecha- 
nism of this enhancement is probably complex and includes 
a reduction in renal vascular esistance, a decrease in 
angiotensin II that may have opposing actions on the kidney 
as compared with atrial natriuretic peptide and decreases in 
cyclic GMP phosphodiesterase activity that are activated by 
angiotensin II. Indeed, the opposing action of angiotensin II 
on atrial natriuretic peptide is importantly supported by the 
work of Showalter t al. (30). who observed a blunting of the 
natriuretic effect o systemically administered atrial natri- 
uretic peptide when angiotensin II was infused through the 
renal artery at a dose without systemic effects, inuicating 
that at normal renal perfusion pressure, intrarenal ngio- 
tensin II can antagonize the natriuretic response to atrial 
natriuretic peptide. 
Wong et al. (36) demonstrated that renal cyclic GMP 
production is the principal mediator of the increase in 
urinary cyclic GMP after administration f exogenous atrial 
natriuretic peptide in normal rats. Results from our labora- 
tory (21) indicate that sodium retention during the evolution 
of congestive heart failure occurs in association with a loss 
of the previously enhanced renal generation ofcyclic GMP 
and with activation of the renin-angiotensinaldosterone 
system. In cultured vascular smooth muscle ells, Smith and 
Lincoln (37) observed that angiotensin II decreased atrial 
natriuretic peptide-stimulated intracellular cyclic GMP accu- 
mulation by stimulating cyclic GMP hydrolysis. This aug- 
mented hydrolysis of cyclic GMP appeared to be mediated 
by calcium-activated cyclic GMP phosphodiesterase. Stud- 
ies (38) have demonstrated that cyclic GMP phosphodiester- 
ase inhibition markedly potentiates the effect of acute vol- 
ume expansion and low dose atrial natriuretic peptide 
infusion on urinary sodium and cyclic GMP excretion, an 
effect hat was attenuated by administration f a monoclonal 
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antibody directed against atria1 natriuretic peptide. These 
studies support an important role cf renal cyclic GMP 
phosphodiesterase modulation for the biologic response to 
endogenous and exogenous atrial natriuretic peptide and a 
key role for angiotensin II in this alteration. 
Cardiac Synthesis of Atrial NaMwetic 
Peptide iu Congestive Heart Failure 
A hallmark of acute and chronic ongestive heart f ilure 
is the elevation of circulating atrial natriuretic peptide levels 
(20.24). This elevation is secondary to enhanced cardiac 
synthesis and release, which are activated by increased 
cardiac volume and pressure overload. Recent investigations 
(39) also support he role of humoral stimulation of atrial 
natriuretic peptide synthesis and release by other local and 
circulating humoral factors. In acute congestive heart fail- 
ure, the increase in circulating atrial natriuretic peptide is 
secondary to release of stored atria! atrial natriuretic pep- 
tide, with enhanced cardiac synthesis maintaining elevated 
levels with more sustained ventricular failure (40). In the 
cardiomyopathic strain of Syrian hamster, the content of 
atrial natriuretic peptide granules within the cardiac atria 
varies inversely with the circulating plasma level of atrial 
natriuretic peptide consistent with incnzed atrial synthesis 
and release (41). It is possible that the synthetic apacity of 
the atria is overwhelmed relative to the demands of the 
system, leading to a state of relative deficiency with chronic 
and severe ventricular dysfunction. Indeed, in dogs with 
chronic congestive heart failure, Redfield et al. (42) demon- 
strated an impaired capacity to release atrial natriuretic 
peptide in response to acute volume expansion with in- 
creases in atrial pressures. Recently, Volpe et al. (43) also 
observed impaired release of atria1 natriuretic peptide in 
humans with dilated cardiomyopathy and mild congestive 
heart failure. Thus, a relative deficiency may occur In 
chronic congestive heart failure with biologic onsequerz~s. 
Congestive heart failure in humans and animals is char- 
acterized by the presence of ventricular atrial natriuretic 
peptide (44). Because ventricular trial natriuretic peptide is 
present in primitive organisms, the occurrence in higher 
species might represent the reactivation f fetal genes (45). 
Protooncogenes that regulate the hypertrophic process in 
cardiomyopathy may also control the r cruitment of ventric- 
ular atrial natriuretic peptide synthesis (46). It has been 
shown in cardiomyopathic amsters that ventricular myo- 
cardium becomes the principal source of atriai natriuretic 
peptide (47). 
A portion of total atrial immunoreactive atrial natriuretic 
peptide in the severely failing human heart is composed of 
beta-atria1 natriuretic peptide, an antiparallel dimer with 
reduced biologic activity (48). In studies from our labora- 
tory, Wei et al. (49) reported that his altered biologic form of 
atrial natriuretic peptide is also elevated inthe circulation of 
patients with severe congestive heart faihrre. Thus, beta- 
atrial natriuretic peptide xists in overt heart failure and may 
have biologic significance for this sodium-retaining and 
vasoconstrictive state. 
Diagnostic and Prognostic Role of Circ&hg 
Atrial Natriuretic Peptide in Congestive 
Heart Failure 
Because of its elevation in chronic congestive heart 
failure (24), circulating atrial natriuretic peptide has emerged 
as an important diagnostic and prognostic serum marker in 
this condition. Repeated studies have demonstrated that 
elevated atrial natriuretic peptide correlates with the func- 
tional class of symptomatic congestive heart failure. Got&b 
et al. (SO) reported that atrial natriuretic peptide provides 
prognostic data on survival, ventricular ectopic activity and 
hemodynamic abnormalities. Davis et al. (51) extended these 
findings and identified atrial natriuretic peptide as a specific 
and sensitive test for predicting the development of conges- 
tive heart failure in elderly subjects. These investigators 
reported that atrial natriuretic peptide could identify patients 
at risk for congestive h art failure, suggesting that it could be 
used in these patients for prevention, early detection and 
treatment. 
We and others have recently focused on the N terminus 
of pro-atrial natriuretic peptide (N-ANP) which is the non- 
biologically active fragment of the prohormone and core- 
leased with the biologic active 28-amino acid C-terminal 
(C-ANP). Because N-ANP is cleared more slowly, it circu- 
lates at higher concentrations than the biologically active 
C-ANP. Moreover, it is more stable in vitro than C-ANP 
(52). In recent studies (53). we examined its specificity and 
sensitivity as a diagnostic test in identifying subjects with 
asymptomatic left ventricular dysfunction as documented 
prospectively with radionuclide angiography and clinical 
characterkation. These studies demonstrated that N-ANP 
was e!evated consistently in patients in New York Heart 
Association functional class I with asymptomatic left ven- 
tricular dysfunction and was more sensitive and specific than 
C-ANP, thus emerging as an important noninvasive serum 
marker in the identitkation f patients with asymptomatic 
left ventricular dysfunction. The diiostic importance of
N-ANP is also underscored byHall et al. (52), who recently 
reported that N-ANP is the most powerful independent 
prognostic indicator in patients with asymptomatic I& ven- 
tricular dysfunction after acute myocardial infarction. 
Inhibition of Atrial Natriuretic Peptide 
Degradation i  the Therapeutics of 
Congestive &art Failure 
Since the discovery ofatria1 natriuretic peptide, strategies 
have emerged to utilize this peptide in the treatment of
disorders of cardiorenal function such as congestive heart 
failure. Therapeutic strategies have included infusion of the 
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peptide and potent&ion of its actions by inhibitors of cyclic 
GW phosphodiesterase (54,55). Recent therapeutic aP- 
pm&es have focused on inhibition of neutral endopepti- 
dase 2~. 11, the enzyme that degrades atrial natriuretic peptide. 
-0 pathways for atrial natriuretic peptide metabolism 
are enzymatic clearance by means of the ectoenzyme n utral 
endopeptidase 24.11 and receptor clearance by means of the 
clearance receptor. Neutral endopeptidase 24.11 is a well 
characterized e&enzyme that is present in numerous tk- 
sues, including kidney, lung, brain and endothelial cells. 
Repeated studies have demonstrated that atrial natriuretic 
peptide is a substrate for neutral endopeptidase 24.11. On 
the basis ofthe high concentration f neutral endopeptidase 
24.11 in renal brush border membranes, Kenny a dStephen- 
son (56) suggested that renal tubular neutral endopeptidase 
24.11 serves a physiologic function of rapidly and efficiently 
degrading liked atrial natriuretic peptide to prevent biolog- 
ically intact pptide from reaching the terminal nephron, 
which is a major site of action. Evidence also suggests hat 
neutral endopeptidase 24.11 activity may be regulated. Such 
a phenomenon may be relevant to disease states uch as 
congestive heart failure in which increased neutral endopep- 
tidase 24.11 activity could attenuate he full biologic a tions 
of elevated endogenous atrial natriuretic peptide. This con- 
cept may be relevant to congestive heart faihue, in which 
some studies (34) support increased neutral endopeptidase 
24.11 activity. 
In acute experimental congestive heart failure, we (57) 
found a parallel increase in urinary cyclic GMP excretion 
and urinary sodium excretion tier neutral endopeptidase 
inhibition together with an increase in urinary atrial natri- 
uretic peptide, suggesting that delivery of atrial natriuretic 
peptide to the terminal nephron indeed may activate cyclic 
GMP and contribute oa natriuretic response. This supports 
the conclusion that neutral endopeptidase 24.11 may limit 
the full natriuretic action of elevated endogenous atriai 
natriuretic peptide in congestive heart failure. Such obser- 
vations are also supported by studies (58) demonstrati~? a 
luminal action of atrial natriuretic peptide in the inner 
meduilary collecting duct to inhibit sodium transport. In 
chronic experimental congestive heart failure, neutral en- 
dopeptidase 24.11 inhibition produces a decrease in atrial 
~ESSUES and an initial maintenance of cardiic output (34). 
Neutral endopeptidase 24.11 inhibition potentiated the natri- 
~'Ctic action of endogenous atrial natriuretic peptide by a 
mechanism independent of systemic or renal hemodynam- 
iCS. More Sbikiflg, this natriuretic action occurred in a model 
of severe congestive heart f ilure that was resistant to the 
tkWiwetiC action of exogenous atrial natriuretic peptide, 
underscoring the potential ellkacy of this form of therapy. 
The observed biologic responses in these studies in acute 
and chronic experimental congestive heart failure were aho 
@eater than that predicted from any increase in circulating 
atrial natriuretic peptide, indicating a local tissue potentia- 
tion of atrial natriuretic peptide (Pii. 3). The unique natri- 
uretic action of neutral endopeptidase 24.11 inhibition may 
pisun 3. Bar graphs of peak changes in plasma atrial uahiuretic 
peptide (ANF), urinary sodium excretion <U,,V) and fractional 
excretion ofsodium (FENa) in congestive h art failure with neutral 
endopeptidase inhibitor (NBP-I) (30 tug/kg), followed by neutral 
endopeptidase inhibitor (60 mgkg) or with exogenous atrial natri- 
uretic peptide (100 ng/kg/min). *p < 0.05 neutral endopeptidase 
inhibitor group vs. atrial natriuretic peptide group. All data are 
expressed asmean value f SEM. Reproduced, with permission, 
from Cavero et al. (34). 
also be associated with cardiovascular and humoral effects. 
Recently, Elsner et al. (59) reported that long-term neutral 
endopeptidase 24.11 inhibition in humans with chronic on- 
gestive heart ftim resulted in favgmble hemodynamic re-
spanses together with suppression f vasoconstrictor humoral 
systems. 
We have already discussed the antagonism of atrial 
natriuretic peptide by the renin-angiotensin-aldosterone sys- 
tem. Such antagonism is also observed in severe congestive 
heart failure to limit the Fidel natriuretic action of neutral 
endopeptidase 24.11 inhibition (60). Long-term angiotensin 
antagonism with angiotensin-converting enzyme inhibition 
potentiated both the renal hemodynamic and excretory 
response toneutral endopeptidase 24.11 inhibition, an effect 
that was a+lk . . . ..d by intrarenal itision of low doOs :%o- 
tensin. These results support the concept that winhibition oi 
both neutral endopeptidase 24.llcsnd angiotensin-converting 
enzyme may emerge as a unique form of therapy in the 
treatment of congestive h art f&u-e. Indeed, in light of the 
knowledge of the delay in onset of symptoms with angiotensin- 
converting enzyme inhiition in asymptomatic I& ventricular 
dysfunction, one could speculate that winhibition of both these 
ectoenzyme systems may emerge as optimal therapy indelay- 
ing the onset of overt wngestive heart failure. 
Future Areas of Atrial Nbriuretic Peptide 
Research in Heart Failure 
Despite great advances in our understanding of atrial 
natriuretic peptide during the last decade, this field of 
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research is still in its infancy. During the last 3 years, two 
additional structurally related peptides, brain natriuretic 
peptide and C-type natriuretic peptide, have been identified. 
All three natriuretic peptides are separate gene products 
(IS). Brain natriuretic peptide like atrial natriuretic peptide is
of cardiac origin and together function as a dual natriuretic 
peptide system (61). C-type natriuretic peptide, not to be 
confused with the C-terminal trial natriuretic peptide, is of 
endothelial origin and functions as a paracrine factor in the 
control of vascular tone (62-65). These natriuretic peptides 
function by means of a family of receptors, which in addition 
to being localized in endothelial cells, vascular smooth 
muscle cells and renal epitSielia1 cells are also expressed in
the myocardium (13,66). In congestive heart failure, brain 
natriuretic peptide and atrial natriuretic peptide are elevated 
in the plasma (61). Although C-type natriuretic peptide is 
present in human plasma, its activity in congestive heart 
failure remains undefined (64). 
The potential of manipulating these peptides as natri- 
urctic and vasoactive factors will be a major area of research 
not only in congestive heart failure but in other cardiovas- 
cular disease states. Specifically, inhibition of the degrada- 
tion of the natriurctic peptides may emerge as a key treat- 
ment of congestive h art failure either as single therapy or 
combined with inhibition of the reninangiotensin-aldoste- 
rone system. In summary, our understanding of natriuretic 
peptides should continue to grow during the 2nd decade after 
the discovery of atrial natriuretic peptide and the role of the 
heart as an endocrine organ. 
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